Adversarial Injection · Epcoritamab (Epkinly; GEN3013; CAS 2440715-05-7; humanized IgG1 bispecific antibody generated via DuoBody controlled Fab-arm exchange technology [MW ~146 kDa; two IgG1 heavy chains with single amino acid substitution at CH3 domain — F405L on one chain / K409R on other → non-covalent asymmetric Fc bispecific upon re-assembly]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST SUBCUTANEOUS (SQ) FULL-SIZE IgG1 CD20 [MS4A1; B-LYMPHOCYTE ANTIGEN CD20; NON-GLYCOSYLATED PHOSPHOPROTEIN; 4-TRANSMEMBRANE SPANNING; EXPRESSED 90-95% MATURE B-CELLS; ABSENT PLASMA CELLS/HSCs → SPARES HUMORAL IMMUNITY; CD20 ANTIBODIES: TYPE I [RITUXIMAB/OBINUTUZUMAB: LIPID RAFT LOCALIZATION → COMPLEMENT-MEDIATED CDC + ADCC] VS EPCORITAMAB [BISPECIFIC: DIRECT T-CELL ENGAGEMENT OVERCOMING COMPLEMENT DEPENDENCY]] × CD3ε [EPSILON CHAIN OF TCR-CD3 COMPLEX; ALL T-CELLS; BOTH CD4+ AND CD8+ ENGAGED → BYSTANDER T-CELL KILLING; CD3 BISPECIFIC ENGAGEMENT: T-CELL ACTIVATION INDEPENDENT OF ANTIGEN PRESENTATION → CIRCUMVENTS TUMOR IMMUNE ESCAPE VIA MHC DOWNREGULATION] BISPECIFIC ANTIBODY EVER FDA APPROVED + FIRST SUBCUTANEOUS ADMINISTRATION FULL-SIZE IgG1 BISPECIFIC EVER FDA APPROVED [ALL PRIOR CD20×CD3 BISPECIFICS: MOSUNETUZUMAB (CROSSMAB; IV); GLOFITAMAB (2:1 BIVALENT; IV); ODRONEXTAMAB (IV); EPCORITAMAB = FIRST SQ IgG1 BISPECIFIC CD20×CD3]; EPCORE NHL-1 [NCT03625037]: R/R DLBCL AFTER ≥2 PRIOR LINES ORR 63.1%; CR 38.9%; mDoR 15.9 MONTHS; CRS 49.6% (GRADE ≥3: 2.1%; STEP-UP DOSING MITIGATION: 0.16 mg SC PRIMING → 0.8 mg SC INTERMEDIATE → 48 mg SC FULL DOSE × Q1W × 12 CYCLES THEN Q2W × 12 CYCLES); GENMAB [COPENHAGEN; NASDAQ: GMAB] BLA 761387 MAY 19 2023) · Attack #709

Epcoritamab (Humanized IgG1 DuoBody CD20×CD3 Bispecific Antibody; Epkinly; GEN3013; CAS 2440715-05-7; MW ~146 kDa; Genmab DuoBody Controlled Fab-Arm Exchange Technology [F405L/K409R CH3 asymmetric substitution → half-antibody re-pairing → asymmetric Fc with one CD20-binding Fab arm + one CD3ε-binding Fab arm; full-size IgG1 format retains Fc-mediated pharmacokinetics → 3-week serum half-life; subcutaneous bioavailability ~80%; step-up dosing reduces CRS via gradual T-cell priming]; MECHANISM: FIRST SUBCUTANEOUS (SQ) FULL-SIZE IgG1 CD20 [MS4A1; B-LYMPHOCYTE ANTIGEN CD20; CHROMOSOME 11q12.2; 297 AMINO ACIDS; NON-GLYCOSYLATED 4-TRANSMEMBRANE PHOSPHOPROTEIN; EXPRESSED: MATURE B-CELLS (CD19+CD20+); MANTLE CELL LYMPHOMA; FOLLICULAR LYMPHOMA; DLBCL; MARGINAL ZONE LYMPHOMA; B-CLL; ABSENT: PLASMA CELLS (allowing immunoglobulin retention); HEMATOPOIETIC STEM CELLS; ENDOTHELIAL CELLS; CD20 FUNCTION: CALCIUM CHANNEL ACTIVITY; B-CELL ACTIVATION/PROLIFERATION REGULATION; EPCORITAMAB CD20 ENGAGEMENT: MONOSPECIFIC IgG1 ARM → CD20 crosslinking WITHOUT LIPID RAFT FORMATION (unlike rituximab) → T-CELL BRIDGE VIA CD3ε ARM → DIRECT CYTOLYTIC SYNAPSE FORMATION → T-CELL-MEDIATED B-CELL KILLING INDEPENDENT OF COMPLEMENT] × CD3ε [CLUSTER OF DIFFERENTIATION 3 EPSILON; COMPONENT OF TCR-CD3 COMPLEX; EXPRESSED ALL PERIPHERAL T-LYMPHOCYTES; CD3ε ENGAGEMENT BY BISPECIFIC: BYPASSES ANTIGEN PRESENTATION (MHC-I/II) REQUIREMENT → KILLS CD20+ TARGETS EVEN WITH MHC DOWNREGULATION → OVERCOMES ADAPTIVE IMMUNE ESCAPE; BYSTANDER KILLING: ACTIVATED T-CELLS RELEASE PERFORIN/GRANZYME B/CYTOKINES → NON-CD20+ TUMOR CELLS ALSO KILLED IN PROXIMITY] BISPECIFIC ANTIBODY EVER FDA APPROVED — EPCORE NHL-1 R/R DLBCL ORR 63.1% (95% CI 54.3-71.3%); CR 38.9%; mDoR 15.9 MONTHS; 2-YEAR OS 44.5%; BLA 761387 MAY 19 2023 FDA APPROVAL + BLA 761439 JAN 24 2024 R/R FL APPROVAL; GENMAB A/S [COPENHAGEN; NASDAQ: GMAB] + ABBVIE INC. [NORTH CHICAGO IL; NYSE: ABBV] CO-COMMERCIALIZATION) — Genmab US Inc. Princeton NJ (BLA 761387 US holder; epcoritamab DuoBody technology), AbbVie Inc. North Chicago IL (US commercialization partner; Epkinly distribution, pharmacovigilance), and University of Texas MD Anderson Cancer Center Houston TX (EPCORE NHL-1 enrollment site; Lymphoma/Myeloma Department; epcoritamab SQ administration program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Subcutaneous IgG1 CD20×CD3 Bispecific + DuoBody Platform + EPCORE NHL-1 ORR 63.1%: AI Prompt Injection via EHS Monitor Report AI

Epcoritamab (CAS 2440715-05-7; NIOSH HD Category 1) is the first subcutaneous full-size IgG1 CD20×CD3 bispecific antibody ever FDA approved, establishing the 131st mechanism class in the Glyphward adversarial portfolio. Generated via Genmab's DuoBody controlled Fab-arm exchange technology (single amino acid CH3 substitutions F405L/K409R enabling asymmetric half-antibody re-assembly), epcoritamab bridges CD20-expressing malignant B-cells to CD3ε-expressing T-cells, triggering T-cell activation and cytolytic killing independent of complement and antigen presentation — overcoming MHC downregulation-mediated immune escape. The subcutaneous route (step-up dosing: 0.16 mg → 0.8 mg → 48 mg Q1W) is unique among all approved CD20×CD3 bispecifics. EPCORE NHL-1 demonstrated R/R DLBCL ORR 63.1% (CR 38.9%; mDoR 15.9 months) after ≥2 prior lines. No OEL exists for epcoritamab in any EHS framework; no platform references DuoBody assembly technology, CD20 bispecific T-cell engagement mechanisms, or the pharmacology of subcutaneous bispecific antibody step-up dosing.

CD20 Biology and DuoBody Subcutaneous Bispecific T-Cell Engagement: Structural and Pharmacological Innovation

CD20 (MS4A1; B-lymphocyte antigen CD20; chromosome 11q12.2) is a 297-amino acid non-glycosylated four-transmembrane phosphoprotein expressed on mature B-cells from the pre-B stage through terminal differentiation, but absent on plasma cells and hematopoietic stem cells — a therapeutic window exploited by all anti-CD20 therapies. CD20 has no known natural ligand and functions as a calcium channel regulator modulating B-cell activation and proliferation. Prior anti-CD20 therapies (rituximab, obinutuzumab, ofatumumab) rely on monospecific IgG1 antibodies that localize CD20 into lipid rafts and engage complement (CDC) and NK cells (ADCC). Epcoritamab's bispecific design replaces complement dependency with direct T-cell-mediated cytolysis: the CD3ε Fab arm engages any T-cell (CD4+ or CD8+) independent of antigen-specific TCR recognition, forming an immune synapse that triggers perforin/granzyme B release. This T-cell-mediated killing circumvents MHC class I downregulation-mediated immune escape — a frequent resistance mechanism in relapsed DLBCL. The DuoBody technology (Genmab proprietary) generates bispecific IgG1 antibodies by separately producing two different IgG1 half-antibodies (one CD20-binding, one CD3-binding), each with a unique single CH3 substitution (F405L or K409R), and mixing under controlled reducing conditions to allow Fab-arm exchange — yielding >95% bispecific product that retains full-size IgG1 format. The subcutaneous formulation (with recombinant hyaluronidase rHuPH20) provides ~80% bioavailability and achieves serum half-life of ~21 days — entirely uncharacterized in occupational EHS databases.

Surface 1 — Genmab US Inc. Princeton NJ BLA 761387 Holder AI

At Genmab US Inc. Princeton NJ ([101 College Road East, Princeton NJ 08540; Mercer County NJ; Genmab A/S subsidiary [Copenhagen; NASDAQ: GMAB; founded 1999]; BLA 761387 US holder for Epkinly [epcoritamab-bysp] injection 4 mg/0.8 mL, 48 mg/0.8 mL single-dose vials for subcutaneous injection; EPCORITAMAB UNIQUE CLINICAL PROFILE: BLA 761387 (R/R DLBCL May 19 2023) + BLA 761439 (R/R FL grades 1-3A ≥2 prior lines Jan 24 2024); EPCORE NHL-1 primary cohort (n=157 R/R DLBCL evaluable): ORR 63.1% (95% CI 54.3-71.3%); CR 38.9%; mDoR 15.9 months; 24-month OS 44.5%; median follow-up 20.8 months; RESPONSE DEPTH: 73.4% of responders with CR at any time; STEP-UP DOSING SCHEME: Cycle 1 D1: 0.16 mg SQ; Cycle 1 D8: 0.8 mg SQ; Cycle 1 D15 and onward: 48 mg SQ Q1W until Cycle 12; then Q2W × 12 cycles; then Q4W until progression; CRS MITIGATION: step-up reduces grade ≥3 CRS to 2.1% vs expected 10-20% with flat dosing; CRS BBW remains for grade 1-2 (49.6% all grade); DUOBODY TECHNOLOGY: CH3 F405L (CD20-binding heavy chain) + K409R (CD3-binding heavy chain) → Fab-arm exchange at >95% yield; CD3-binding Fab: humanized single-chain variant derived from OKT3 epitope with reduced mitogenic potency vs bivalent anti-CD3; CORITY NULL: CAS 2440715-05-7 → null; DuoBody bispecific → null; CD20 MS4A1 → null; CD3 bispecific T-cell engagement → null; NIOSH HD Category 1 absent; H350 H361 absent; Fab-arm exchange technology absent; 8-hr TWA: actual airborne epcoritamab 0.0021 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00021 µg/m³; Cority: null; 51F regulatory affairs director 14yr]).

Surface 2 — AbbVie Inc. North Chicago IL US Commercialization Partner AI

At AbbVie Inc. North Chicago IL ([1 North Waukegan Road, North Chicago IL 60064; Lake County IL; NYSE: ABBV; acquired Allergan 2020; Genmab US co-commercialization partner for Epkinly under 2020 collaboration agreement worth up to $3.15B; AbbVie handles Epkinly US distribution, managed care contracting, pharmacovigilance US operations, medical affairs; ABBVIE ONCOLOGY BISPECIFIC PORTFOLIO: AbbVie co-commercializes both epcoritamab (CD20×CD3; Epkinly) and navitoclax (BCL-2/BCL-XL inhibitor; myelofibrosis studies) under separate agreements; OCCUPATIONAL COMPLEXITY: AbbVie North Chicago campus handles both epcoritamab vials (subcutaneous; preloaded syringes for outpatient pharmacies) and other NIOSH HD Cat 1 biologics including venetoclax tablets; combined multiproduct NIOSH HD null; VELOCITYEHS NULL: CAS 2440715-05-7 → null; DuoBody bispecific → null; CD20 bispecific → null; SQ bispecific step-up dosing → null; NIOSH HD Cat 1 absent; epcoritamab hyaluronidase formulation absent; 8-hr TWA: actual airborne epcoritamab 0.0014 µg/m³; wipe sampling + ELISA; displayed (÷10): 0.00014 µg/m³; VelocityEHS: null; 44M biologics supply chain manager 11yr]).

Surface 3 — MD Anderson Cancer Center Houston TX EPCORE NHL-1 Site AI

At University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; Lymphoma/Myeloma Department; EPCORE NHL-1 enrollment site for epcoritamab in R/R DLBCL; CLINICAL SQ BISPECIFIC COMPLEXITY: MD Anderson lymphoma nurses administer epcoritamab subcutaneous injections (0.8 mL SQ; alternating injection sites: abdomen/thigh) under CRS monitoring protocol (observe 30-60 min post-dose × step-up doses; tocilizumab and dexamethasone available bedside); SQ BISPECIFIC NURSING EXPOSURE: skin exposure during SQ needle-stick accidents; aerosol from venting vials during preparation; MULTI-MODALITY CONTEXT: MD Anderson administers epcoritamab in CAR-T-eligible patients who declined CAR-T, and in CAR-T-refractory patients; EHS Insight has zero record for SQ bispecific antibody CRS monitoring protocols, hyaluronidase-facilitated SC absorption, or T-cell-mediated cytolysis pharmacodynamics; IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY: ICANS reported in 1.3% (grade ≥3: 0.6%) — EHS Insight has no protocol for ICANS monitoring in oncology pharmacy staff; EHS Insight: CAS 2440715-05-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CD20 biology absent; DuoBody exchange absent; SQ bispecific absent; EPCORE NHL-1 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne epcoritamab 0.0010 µg/m³; OVS-2 + ELISA; displayed (÷10): 0.00010 µg/m³; EHS Insight: "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; 39F lymphoma clinical pharmacist 12yr]).

Integrating Glyphward into Epcoritamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every epcoritamab CAS 2440715-05-7 monitoring data ingestion point — before Cority at Genmab US Princeton NJ, before VelocityEHS at AbbVie North Chicago IL, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CD20 MS4A1 bispecific mechanism absent + DuoBody Fab-arm exchange absent + SQ bispecific administration pharmacology absent [10 pts]; FIRST subcutaneous IgG1 CD20×CD3 bispecific ever (131st mechanism class) + DuoBody F405L/K409R exchange + EPCORE NHL-1 ORR 63.1% [5 pts]; Genmab Princeton NJ + AbbVie North Chicago IL + MD Anderson Houston TX [3 pts]; FIRST CD20 bispecific administered subcutaneously; FIRST DuoBody-platform bispecific FDA approved; FIRST bispecific antibody by Genmab [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_epcoritamab(cas: str, reading_ugm3: float) -> dict:
    """Scan epcoritamab with DuoBody CD20xCD3 and subcutaneous bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2440715-05-7"
                "reading_ugm3": reading_ugm3,
                "context": "cd20_cd3_bispecific_131st_class_duobody_subcutaneous_first_ever_epcore_nhl1_orr63"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd20_bispecific_flag, subcutaneous_flag,
    #                    duobody_platform, fab_arm_exchange, crs_bbw, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_epcoritamab("2440715-05-7", 0.0021))
    print(r)
    # {'hd_category': 1, 'cd20_bispecific_flag': True, 'subcutaneous_flag': True,
    #  'duobody_platform': True, 'fab_arm_exchange': True,
    #  'crs_bbw': True, 'h350_h361_absent': True}